Other languages TaiMed Biologics Inc.

Equities

4147

TW0004147004

End-of-day quote Taipei Exchange Other stock markets 03:30:00 03/05/2024 am IST			5-day change	1st Jan Change
85.8 ^TWD	+0.94%		+3.37%	+4.63%

20/03	TaiMed Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
13/03	Taimed Biologics and AcedrA Biopharmaceticals Partner to Commercialize Trogarzo in the Middle East and North Africa Region	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

TaiMed Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	20/03
Taimed Biologics and AcedrA Biopharmaceticals Partner to Commercialize Trogarzo in the Middle East and North Africa Region	14/03
Taimed Announces Its Marketing Partner Received Refusal to File Letter for Trogarzo Intramuscular Method of Administration sBLA from the US FDA	28/02
TaiMed Biologics Inc. Receives Patent Approval from the Taiwan Intellectual Property Office for Improving the Pharmacokinetic Performance of TMB-365 Using Histidine Modification Technology	21/02
TaiMed Biologics Inc. Announces US FDA Grants Fast Track Designation to TMB-365/TMB-380 Long-Acting Combination Therapy for HIV Infection	07/02
TaiMed Biologics Inc. Revises the Phase 2 Clinical Study Design of Bi-Monthly Dosing of TMB-365/TMB-380 Combination for the Treatment of HIV Infection	21/12
Taimed Biologics Inc. Announces US FAD Approves the sBLA for the IV Push Administration of the Loading Dose of Trogarzo	13/12
TaiMed Biologics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
TaiMed Biologics Inc. Announces Results from Trogarzo Intramuscular (IM) Administration Study	13/23/13
TaiMed Biologics Inc. Completes Data Analysis of the Clinical Trial Sentinel Group for the TMB-365 and TMB-380 Combination as Expected and Confirms the Dosing for Future Execution	06/23/06
TaiMed Biologics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/23/11
TaiMed Biologics Inc. Completes the Last Patient Visit of the Sentinel Group in the Clinical Study Evaluating Long-Acting TMB-365/TMB-380 Combination Maintenance Therapy	29/23/29
TaiMed Biologics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/23/12
TaiMed Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	10/23/10
TaiMed Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	10/23/10
TaiMed Biologics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	11/22/11
US FDA Approves the Supplemental Biologicslicense Application for Intravenous (IV) Pushadministration of Trogarzo	04/22/04
TaiMed Biologics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	15/22/15
TaiMed Biologics Inc. Announces First Patient Enrolled in the Study Evaluating Bi-monthly and Quarterly Dosing of the Long-Acting TMB-365/TMB-380 mAb Combination Maintenance Therapy	29/22/29
Tanvex Biopharma and Taimed Biologics Form a Business Alliance to Offer Efficient CDMO Services in Biologics	14/22/14

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages TaiMed Biologics Inc.

Equities

4147

TW0004147004

Other languages

Filters